Is Becton, Dickinson and Company (BDXA) a Buy, Sell, or Hold?
NYSE : BDXA
Becton, Dickinson and Company
$59.24 USD
-$1.36 (-2.24%)
- Volume
- 6.15M
- Average Volume
- 0
- Market Capitalization
- $55.91B
- P/E Ratio
- 40.16
- Dividend Yield
- 2.36%
- Price Target
- Year High
- $64.12
- Year Low
- $49.07
- Day High
- —
- Day Low
- —
- Payout Ratio
- $1.04
- Current Ratio
- $0.94
| Source | Headline |
|---|---|
|
Becton, Dickinson: Value Or Overvalued Even Now?
Becton, Dickinson is rated a 'BUY' under $160/share, driven by attractive fundamentals and a conservative valuation approach. Despite the recent spin-off of its high-margin bioscience segment, BDX retains core medtech operations with solid profitability and robust cash flow generation. I see BDX's current 13x P/E as undervalued, with a fair value target of $215/share by 2028E and an annualized return above 15% at current prices. seekingalpha.com - 2026-04-20 06:35:45 |
